Skin ConditionNCT07271199
Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum
A study testing Experimental formula in people with Skin Condition and Eyelash Growth, run by Hungkuang University at 1 site in Taiwan.
Trial summary
This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Read more about this study
- Who is it for?
- Ages 18 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Skin Condition, Eyelash Growth, Eyelashes
- What is being tested?
- Experimental formula
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Nov 2025to 26 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy female adults from the age of 18 to 60 years (inclusive).
- Having symptoms of alopecia, baldness, or self-identified with hair thinning.
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Who cannot join
- Currently taking any medication or using any eyelash care products.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Eyelash Care Effects of Premium Rejuvenation Eyelash Serum
This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Participants will apply the product twice daily for 56 days (8 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 56), participant will be asked to fill out a questionnaire on the usage of the intervention and self evaluation of eyelash condition.
Read the detailed description
This prospective, randomized, double-blinded, placebo-controlled study aims to investigate the effects of Premium Rejuvenation Eyelash Serum on eyelashes and surrounding periorbital skin. A total of 30 healthy female adults aged 18 to 60 will be enrolled. Inclusion criteria require participants to be free from chronic diseases, major illnesses (including cancer, stroke-related disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, or major organ/hematopoietic stem cell transplants), and allergic constitutions. Exclusion criteria include current use of medications or eyelash care products.
Participants will be randomly assigned into two groups of 15 each: Group 1 uses placebo (Base formula without active ingredient); Group 2 uses the experimental formula with ginger (Zingiber officinale)-derived extracellular vesicle + turmeric (Curcuma longa)-derived extracellular vesicles + IGF-1 + FGF-7. Baseline assessments will be conducted prior to product use. Follow-up assessments will occur at Days 28 (4 weeks) and 56 (8 weeks). Evaluations will include eyelash density, change in eyelash length, self-reported periorbital skin condition (e.g., swelling, irritation, pigmentation, redness, and allergic reactions), and a questionnaire. Eyelash parameters will be objectively measured using the Canfield Scientific VISIA® Skin Analysis System. At the conclusion of the study (Day 56), participant self-assessments on the intervention and eyelash condition will be evaluated through a questionnaire.
- Conditions
- Skin Condition, Eyelash Growth, Eyelashes, Skin Health, Hair Health
- Being tested
- Placebo control, Experimental formula
- Keywords
- Eyelash, Eyelash health, Skin health, Eyelash condition, Hair health, Product formulation, Growth factors, Extracellular vesicle, Ginger, Turmeric
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo controlOther
Placebo Control (Base Formula without active ingredients). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat application twice daily, in the morning and evening.
Experimental formulaOther
Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7).
After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat this application twice daily, in the morning and evening.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Placebo control | Placebo comparator | Base formula without active ingredient Receives: Other: Placebo control |
| Group 2: Experimental formula | Experimental | Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). Receives: Other: Experimental formula |
What is being measured
The primary outcome is the main question the study is designed to answer.
Eyelash density
Assess eyelash density with Canfield VISIA® Skin Analysis system by assigning score from 1 (most dense, thick eyelashes) to 5 (least dense, thin eyelashes). Results will be expressed as percentage of change in eyelash density percentage relative to Day 0.
Measured: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)
Eyelash length
Assess eyelash length with Canfield VISIA® Skin Analysis system by assigning score from 1 (longest eyelashes) to 5 (shortest eyelashes). Results will be expressed as percentage of change in eyelash length percentage relative to Day 0
Measured: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)
Secondary outcomes (1)
Participant self-assessment
Participants will be asked to fill out an assessment form with score from 0 to 5 for each of the eyelash condition and product feedback evaluated.
Measured: Day 56 (End of the study period)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2025
- Study start1 Nov 2025
- Primary completion26 May 2026
- Study completion26 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hungkuang University
- Sponsor type
- University, hospital or other
- Collaborators
- Schweitzer Biotech Company
- Responsible party
- Principal investigator, Tsong-Min Chang, Hungkuang University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07271199
- Sponsor's protocol ID
- 25-089-A
- Status last verified
- Jun 2026
- First submitted
- 27 Nov 2025
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Eyelash Care Effects of Premium Rejuvenation Eyelash Serum
- ClinicalTrials.gov ID
- NCT07271199
- Acronym / sponsor ID
- 25-089-A
- Conditions
- Skin Condition, Eyelash Growth, Eyelashes, Skin Health, Hair Health
- Keywords
- Eyelash, Eyelash health, Skin health, Eyelash condition, Hair health, Product formulation, Growth factors, Extracellular vesicle
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Hungkuang UniversityUniversity, hospital or other
- Collaborators
- Schweitzer Biotech Company
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- 26 May 2026 (actual)
- Study completion
- 26 May 2026 (actual)
- First posted
- 9 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Participants will apply the product twice daily for 56 days (8 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 56), participant will be asked to fill out a questionnaire on the usage of the intervention and self evaluation of eyelash condition.
Detailed description
This prospective, randomized, double-blinded, placebo-controlled study aims to investigate the effects of Premium Rejuvenation Eyelash Serum on eyelashes and surrounding periorbital skin. A total of 30 healthy female adults aged 18 to 60 will be enrolled. Inclusion criteria require participants to be free from chronic diseases, major illnesses (including cancer, stroke-related disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, or major organ/hematopoietic stem cell transplants), and allergic constitutions. Exclusion criteria include current use of medications or eyelash care products.
Participants will be randomly assigned into two groups of 15 each: Group 1 uses placebo (Base formula without active ingredient); Group 2 uses the experimental formula with ginger (Zingiber officinale)-derived extracellular vesicle + turmeric (Curcuma longa)-derived extracellular vesicles + IGF-1 + FGF-7. Baseline assessments will be conducted prior to product use. Follow-up assessments will occur at Days 28 (4 weeks) and 56 (8 weeks). Evaluations will include eyelash density, change in eyelash length, self-reported periorbital skin condition (e.g., swelling, irritation, pigmentation, redness, and allergic reactions), and a questionnaire. Eyelash parameters will be objectively measured using the Canfield Scientific VISIA® Skin Analysis System. At the conclusion of the study (Day 56), participant self-assessments on the intervention and eyelash condition will be evaluated through a questionnaire.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Placebo control | Placebo comparator | Other: Placebo controlBase formula without active ingredient |
| Group 2: Experimental formula | Experimental | Other: Experimental formulaBase formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy female adults from the age of 18 to 60 years (inclusive).
- Having symptoms of alopecia, baldness, or self-identified with hair thinning.
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coronary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Key exclusion criteria (1 listed)
- Currently taking any medication or using any eyelash care products.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo controlPlacebo Control (Base Formula without active ingredients). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat application twice daily, in the morning and evening. | Other | Group 1: Placebo control |
| Experimental formulaBase formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat this application twice daily, in the morning and evening. | Other | Group 2: Experimental formula |
Primary outcome
Eyelash density
Time frame: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)
Assess eyelash density with Canfield VISIA® Skin Analysis system by assigning score from 1 (most dense, thick eyelashes) to 5 (least dense, thin eyelashes). Results will be expressed as percentage of change in eyelash density percentage relative to Day 0.
Eyelash length
Time frame: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)
Assess eyelash length with Canfield VISIA® Skin Analysis system by assigning score from 1 (longest eyelashes) to 5 (shortest eyelashes). Results will be expressed as percentage of change in eyelash length percentage relative to Day 0
1 secondary outcome
Participant self-assessment
Time frame: Day 56 (End of the study period)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
Related trials for Skin Condition
RecruitingObservational study
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Dermatologic Conditions, Healthy Volunteers
RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Areata Alopecia, Alopecia
RecruitingPhase 3
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Actinic Keratosis
RecruitingPhase 3
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Actinic Keratosis
Active, not recruiting
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
Skin Laxity, Wrinkle
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental formula in people with Skin Condition and Eyelash Growth, run by Hungkuang University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Eyelash density (time frame: Assessment conducted every 28 days from Day 0 to Day 56 (including Day 0 as baseline)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026; AzTrials last refreshed its copy on 6 Nov 2026.